Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Mesa Laboratories Inc

Technology US MLAB

108.25USD
-0.21(0.19%)

Last update at 2026-06-09T15:52:00Z

Day Range

108.25113.99
LowHigh

52 Week Range

82.59144.98
LowHigh

Fundamentals

  • Previous Close 108.46
  • Market Cap616.27M
  • Volume72833
  • P/E Ratio672.06
  • Dividend Yield0.57%
  • EBITDA35.75M
  • Revenue TTM212.87M
  • Revenue Per Share TTM39.60
  • Gross Profit TTM 116.55M
  • Diluted EPS TTM0.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -0.38900M 3.57M 2.30M 3.43M 8.62M
Minority interest - - - - -
Net income 0.93M 1.87M 3.27M 1.35M 7.48M
Selling general administrative 72.44M 60.31M 45.70M 37.83M 31.30M
Selling and marketing expenses 37.44M 28.31M 18.48M 12.91M 8.26M
Gross profit 133.69M 109.09M 87.01M 64.93M 60.92M
Reconciled depreciation 33.82M 25.07M 17.66M 12.99M 9.43M
Ebit -30.50400M -20.36600M -5.30200M -4.90000M 25.93M
Ebitda 3.32M 4.70M 12.36M 8.09M 35.36M
Depreciation and amortization 33.82M 25.07M 17.66M 12.99M 9.43M
Non operating income net other 1.06M - -2.03100M 1.44M -1.15800M
Operating income -30.50400M -20.36600M -5.30200M -4.90000M 9.78M
Other operating expenses 215.76M 179.63M 121.58M 109.89M 85.28M
Interest expense 3.71M 3.88M 8.02M 5.50M 0.00000M
Tax provision -1.31900M 1.70M -0.97100M 2.08M 1.14M
Interest income - - 0.11M 0.96M -
Net interest income -4.77000M -3.88500M -7.91700M -4.54400M -
Extraordinary items - - - - -0.04300M
Non recurring - - 0.09M 0.35M 8.07M
Other items - - - - -
Income tax expense -1.31900M 1.70M -0.97100M 2.08M 1.14M
Total revenue 219.08M 184.34M 133.94M 117.69M 103.14M
Total operating expenses 130.37M 104.39M 74.66M 57.14M 43.06M
Cost of revenue 85.39M 75.25M 46.92M 52.75M 42.22M
Total other income expense net 30.11M 23.94M 7.61M 8.33M -9.23200M
Discontinued operations - - - - -
Net income from continuing ops 0.93M 1.87M 3.27M 1.35M 7.48M
Net income applicable to common shares 0.93M 1.87M 3.27M 1.35M 7.48M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 661.83M 707.37M 600.15M 420.21M 156.77M
Intangible assets 18.23M 250.12M 111.74M 119.87M 33.22M
Earning assets - - - - -
Other current assets 86.06M 74.97M 39.14M 41.41M 1.60M
Total liab 268.35M 313.57M 193.92M 200.19M 45.46M
Total stockholder equity 393.48M 393.80M 406.23M 220.01M 111.31M
Deferred long term liab 34.03M - 16.27M 32.55M -
Other current liab 19.95M 22.81M 18.31M 14.69M 14.67M
Common stock 332.08M 313.46M 317.65M 158.02M 39.82M
Capital stock 332.08M 313.46M 317.65M 158.02M 39.82M
Retained earnings 74.20M 76.67M 72.46M 71.93M 73.30M
Other liab 35.97M 39.71M 193.92M 32.65M 1.18M
Good will 286.44M 291.17M 160.84M 141.54M 66.38M
Other assets 2.76M 554.43M 275.14M 11.46M 1.32M
Cash 32.91M 49.35M 263.87M 81.38M 10.19M
Cash and equivalents - - - - -
Total current liabilities 43.36M 48.05M 32.58M 26.01M 23.66M
Current deferred revenue 14.41M 14.58M 8.78M 6.81M 3.96M
Net debt 137.36M 171.79M -117.16700M 59.99M 12.55M
Short term debt 2.87M 2.77M 1.02M 1.09M 2.12M
Short long term debt - - - - 2.12M
Short long term debt total 170.27M 221.13M 146.70M 141.37M 22.74M
Other stockholder equity -12.79500M 323.13M 16.12M 0.06M 0.18M
Property plant equipment 28.15M 28.62M 22.00M 22.07M 22.23M
Total current assets 118.97M 124.32M 303.01M 122.79M 33.62M
Long term investments - - - - -
Net tangible assets 107.04M 393.80M 294.49M -41.39400M 44.93M
Short term investments - - - - -
Net receivables 42.55M 41.22M 23.79M 21.13M 12.52M
Long term debt 183.27M 218.37M 145.68M 140.28M 20.61M
Inventory 34.64M 24.61M 11.18M 14.23M 6.77M
Accounts payable 6.13M 7.90M 4.47M 3.41M 2.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -12.79500M 3.67M 16.12M -9.94000M -1.81500M
Additional paid in capital - - - - -
Common stock total equity 332.08M - 317.65M 158.02M 39.82M
Preferred stock total equity - - - - -
Retained earnings total equity 74.20M - 72.46M 71.93M 73.30M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 208.96M 11.83M 275.14M 275.35M 0.25M
Deferred long term asset charges - - - - -
Non current assets total 542.86M 583.05M 297.14M 297.41M 123.14M
Capital lease obligations 2.87M 2.77M 1.02M 1.09M -
Long term debt total 183.27M - 145.68M 140.28M 20.61M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -9.49400M -305.22500M -1.99200M -185.58500M -3.88000M
Change to liabilities -4.90500M 3.96M 0.65M -2.20800M 6.57M
Total cashflows from investing activities -9.49400M -305.22500M -1.99200M -185.58500M -3.88000M
Net borrowings -36.00000M 49.00M -0.66400M 144.07M -23.62500M
Total cash from financing activities -33.32800M 52.58M 146.23M 231.28M -21.67200M
Change to operating activities -3.87000M -3.35100M 2.56M -2.57900M 2.58M
Net income 0.93M 1.87M 3.27M 1.35M 7.48M
Change in cash -16.43600M -214.51900M 182.49M 71.19M 4.72M
Begin period cash flow 49.35M 263.87M 81.38M 10.19M 5.47M
End period cash flow 32.91M 49.35M 263.87M 81.38M 10.19M
Total cash from operating activities 27.98M 39.22M 37.07M 26.56M 30.55M
Issuance of capital stock 0.00000M 0.00000M 145.94M 85.00M -
Depreciation 33.82M 25.07M 17.66M 12.99M 9.43M
Other cashflows from investing activities -4.95000M - - -184.08700M -2.61800M
Dividends paid 3.41M 3.34M 3.17M 2.72M 2.46M
Change to inventory -10.18200M -1.04500M 0.93M 0.41M 2.57M
Change to account receivables -2.12100M -6.75200M -0.64700M -1.66500M 1.59M
Sale purchase of stock 7.00M -0.87500M 150.36M 177.44M -5.09500M
Other cashflows from financing activities 6.08M 76.92M 3.46M -5.44100M 6.42M
Change to netincome 10.34M 19.48M 11.32M 6.92M 5.78M
Capital expenditures 4.54M 4.43M 1.99M 1.50M 1.26M
Change receivables -2.12100M - -0.64700M -1.66500M 1.59M
Cash flows other operating 1.03M - 7.16M 10.11M 4.61M
Exchange rate changes - - - -1.05600M -0.28600M
Cash and cash equivalents changes -14.83900M - 181.31M 71.19M 4.72M
Change in working capital -17.11200M -7.19200M 5.25M -3.13700M 7.89M
Stock based compensation 12.54M 11.39M 9.27M 5.53M 4.21M
Other non cash items 1.30M 7.96M 5.12M 11.80M 4.01M
Free cash flow 23.44M 34.79M 35.08M 25.06M 29.29M

Peer Comparison

Sector: Technology Industry: Scientific & Technical Instruments

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MLAB
Mesa Laboratories Inc		 -0.21 0.19% 108.25 672.06 35.21 2.66 1.41 3.64 19.89
KYCCF
Keyence		 -5.03 1.05% 472.00 41.66 38.76 0.11 5.69 0.10 0.19
COHR
Coherent Inc		 -33.07 8.23% 368.86 333.78 46.73 10.24 7.63 10.78 62.92
GRMN
Garmin Ltd		 0.27 0.11% 235.50 30.87 28.41 7.05 5.74 6.75 23.69
HXGBY
Hexagon AB ADR		 0.16 1.54% 10.55 33.46 33.33 6.00 2.83 6.50 29.28

Reports Covered

Stock Research & News

View All

Profile

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982

Mesa Laboratories Inc

12100 West Sixth Avenue, Lakewood, CO, United States, 80228

Key Executives

Name Title Year Born
Mr. Gary M. Owens CEO, Pres & Director 1968
Mr. John V. Sakys VP, CFO & Chief Accounting Officer 1969
Mr. Brian David Archbold Sr. VP of Continuous Improvement 1976
Mr. Bryan T. Leo Sr. VP of Operations NA
Mr. Garrett Krushefski Sr. VP of Operations NA
Mr. Peter M. Dansky Pres of Clinical Genomics 1961
Mr. Gary M. Owens CEO, President & Director 1968
Mr. Brian David Archbold Senior Vice President of Continuous Improvement 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions